Ademetionine |
| カタログ番号GC10677 |
アデメチオニン (S-アデノシル メチオニン) は、酵素メチオニン アデノシルトランスフェラーゼの作用によってメチオニンと ATP から内因的に生成され、重要な経口活性メチル基供与体です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 29908-03-0
Sample solution is provided at 25 µL, 10mM.
Ademetionine (S-Adenosyl methionine; AdoMet; SAMe) is an endogenous molecule generated from methionine and ATP by the action of methionine adenosyltransferase and plays an important role in cellular metabolism as the main methyl donor [1]. Ademetionine can be used as a drug to treat depression, liver disease, fibromyalgia and osteoarthritis [2]. Ademetionine can also be used as a dietary supplement to support bone and joint health and emotional health [3].
In vitro, ademetionine (300µM) treatment of head and neck squamous cell carcinoma cell lines (Cal-33 and JHU-SCC-011) for 24 or 48h induced a decrease in the G1 phase and G2/M phase cell populations from 44.6% to 28.4% and from 14.7% to 7.6%, respectively, while the S phase cell population increased significantly from 36.1% to 61%, attenuated cell cycle progression, and inhibited cell migration [4]. Ademetionine (500µM) treatment of triple-negative human breast cancer cell lines (MDA-MB-468 and MDA-MB-231) for 24 or 48h upregulated the expression of intracellular miR-34c and miR-449a and promoted cell apoptosis[5].
In vivo, oral treatment of mice with valproate-induced autistic-like behavior with ademetionine (30mg/kg) for 3 days prevented the development of symptoms and normalized the redox potential of the prefrontal cortex[6]. Oral treatment of rats with pentylenetetrazol-induced epilepsy with ademetionine (100mg/kg) prolonged the latency period of epileptic seizures and reduced the severity score of epileptic seizures[7].
References:
[1] Brula M, Cupp M J, Tracy T S. SAMe (S-adenosyl-l-methionine)[M]//Dietary Supplements: Toxicology and Clinical Pharmacology. Totowa, NJ: Humana Press, 2003: 321-334.
[2] Lu S C, Mato J M. S-adenosylmethionine in liver health, injury, and cancer[J]. Physiological reviews, 2012, 92(4): 1515-1542.
[3] Najm W I, Reinsch S, Hoehler F, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial.[ISRCTN36233495][J]. BMC musculoskeletal disorders, 2004, 5: 1-15.
[4] Mosca L, Minopoli M, Pagano M, et al. Effects of S-adenosyl-L-methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms[J]. International Journal of Oncology, 2020, 56(5): 1212-1224.
[5] Coppola A, Ilisso C P, Stellavato A, et al. S-Adenosylmethionine inhibits cell growth and migration of triple negative breast cancer cells through upregulating MiRNA-34c and MiRNA-449a[J]. International Journal of Molecular Sciences, 2020, 22(1): 286.
[6] Ornoy A, Weinstein-Fudim L, Tfilin M, et al. S-adenosyl methionine prevents ASD like behaviors triggered by early postnatal valproic acid exposure in very young mice[J]. Neurotoxicology and teratology, 2019, 71: 64-74.
[7] Dhediya R M, Joshi S S, Gajbhiye S V, et al. Evaluation of antiepileptic effect of S-adenosyl methionine and its role in memory impairment in pentylenetetrazole-induced kindling model in rats[J]. Epilepsy & Behavior, 2016, 61: 153-157.
| Cell experiment [1]: | |
Cell lines | Cal-33、JHU-SCC-011 cells |
Preparation Method | The Cal-33 and JHU-SCC-011 cells were seeded in 6-well plates. The following day, the cells were treated with 300 µM Ademetionine, recovered with trypsin-EDTA after 24 and 48 h, respectively. |
Reaction Conditions | 300 µM; 24、48h |
Applications | Following Ademetionine treatment, the G1 and G2/M phase populations decreased from 44.6 to 28.4% and from 14.7 to 7.6%, respectively, with a concomitant significant increase from 36.1 to 61% of cells in the S phase. |
| Animal experiment [2]: | |
Animal models | Valproic acid treated young mice |
Preparation Method | Mice were injected on postnatal day 4 with one dose of 300 mg/kg of Valproic acid, with normal saline (controls) or with Valproic acid and Ademetionine that was given orally for 3 days at the dose of 30 mg/kg body weight. |
Dosage form | 30mg/kg; p.o. |
Applications | Ademetionine prevents (VPA)-induced autistic like behavior in mice and normalizes redox potential in the prefrontal cortex. |
References: | |
| Cas No. | 29908-03-0 | SDF | |
| Chemical Name | (2S)-2-amino-4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate | ||
| Canonical SMILES | C[S+](C[C@](O1)([H])[C@](O)([H])[C@](O)([H])[C@]1([H])N2C=NC(C2=NC=N3)=C3N)CC[C@@](N)([H])C([O-])=O | ||
| Formula | C15H22N6O5S | M.Wt | 398.44 |
| 溶解度 | DMSO : 79mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5098 mL | 12.5489 mL | 25.0979 mL |
| 5 mM | 0.502 mL | 2.5098 mL | 5.0196 mL |
| 10 mM | 0.251 mL | 1.2549 mL | 2.5098 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *